{"id":"apretude","_chembl":{"chemblId":"CHEMBL2403238","moleculeType":"Small molecule","molecularWeight":"405.36"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=APRETUDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:03:45.902743+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=APRETUDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:04:01.244058+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Human immunodeficiency virus type 1 integrase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:04:02.329332+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2403238/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:04:01.990464+00:00"}},"_dailymed":{"setId":"4338428e-43d4-4e02-ac9d-bd98e738a7da","title":"APRETUDE (CABOTEGRAVIR) KIT [VIIV HEALTHCARE COMPANY]"},"_scrapedAt":"2026-03-27T23:42:30.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:04:03.687539+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07199335","phase":"PHASE4","title":"Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-24","conditions":"HIV, Substance Use Disorder (SUD), Injection Drug Use","enrollment":100},{"nctId":"NCT05986084","phase":"PHASE4","title":"Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-11-30","conditions":"Pre-Exposure Prophylaxis (PrEP), Breast Feeding","enrollment":500},{"nctId":"NCT05514509","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-10-28","conditions":"HIV Infections","enrollment":370},{"nctId":"NCT06134362","phase":"PHASE3","title":"Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-05-14","conditions":"HIV Infections","enrollment":3508},{"nctId":"NCT05374525","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-05-18","conditions":"HIV Infections","enrollment":287},{"nctId":"NCT06145854","phase":"","title":"Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Midway Specialty Care Center","startDate":"2024-01-02","conditions":"Hiv","enrollment":100},{"nctId":"NCT05867212","phase":"","title":"Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.","status":"COMPLETED","sponsor":"Kelley-Ross & Associates, Inc.","startDate":"2023-05-13","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT05072093","phase":"PHASE4","title":"Parrying the Pitfalls of PrEP: Project PEACH","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-11-20","conditions":"HIV, STI","enrollment":240},{"nctId":"NCT05755204","phase":"","title":"A Pharmacist-run PrEP Program for Women","status":"TERMINATED","sponsor":"Orlando Immunology Center","startDate":"2023-06-21","conditions":"HIV Prevention","enrollment":2},{"nctId":"NCT06807736","phase":"","title":"PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.","status":"RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2024-02-13","conditions":"HIV Infection, Sexual and Reproductive Health","enrollment":1800},{"nctId":"NCT05515770","phase":"PHASE3","title":"The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir","status":"RECRUITING","sponsor":"Evandro Chagas National Institute of Infectious Disease","startDate":"2022-09-20","conditions":"HIV Infections","enrollment":1200},{"nctId":"NCT06138600","phase":"PHASE3","title":"Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2023-11-01","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT06250504","phase":"PHASE3","title":"Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT","status":"RECRUITING","sponsor":"Africa Health Research Institute","startDate":"2024-02-27","conditions":"HIV Infections","enrollment":2000},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT05949203","phase":"","title":"Oregon PrEP at Home Study","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2023-12-01","conditions":"HIV/AIDS","enrollment":125}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"INJECTION SITE PAIN"},{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"GAIT DISTURBANCE"},{"count":2,"reaction":"INFLUENZA LIKE ILLNESS"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PYREXIA"},{"count":2,"reaction":"RASH PRURITIC"},{"count":2,"reaction":"THERAPY INTERRUPTED"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ABDOMINAL PAIN"}],"crossReferences":{"chemblId":"CHEMBL2403238"},"_approvalHistory":[{"date":"20231213","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215499"},{"date":"20230227","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215499"},{"date":"20211220","type":"ORIG","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215499"},{"date":"20250411","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215499"},{"date":"20240920","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215499"}],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"APRETUDE","genericName":"APRETUDE","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:04:03.687539+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}